# Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma

> **NCT00261612** · PHASE2 · UNKNOWN · sponsor: **Medical University of Vienna** · enrollment: 16 (—)

## Conditions studied

- Lymphoma, Mantle-Cell

## Interventions

- **DRUG:** bortezomib
- **DRUG:** rituximab
- **DRUG:** dexamethasone
- **PROCEDURE:** treatment protocol

## Key facts

- **NCT ID:** NCT00261612
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2005-01
- **Primary completion:** —
- **Final completion:** 2007-01
- **Target enrollment:** 16 (—)
- **Last updated:** 2006-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00261612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00261612, "Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00261612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*